PGI36 ESTIMATION OF THE MINIMAL IMPORTANT DIFFERENCES IN EUROQOL-5 DIMENSIONS (EQ-5D) FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION

May 1, 2020, 00:00
10.1016/j.jval.2020.04.390
https://www.valueinhealthjournal.com/article/S1098-3015(20)30578-7/fulltext
Title : PGI36 ESTIMATION OF THE MINIMAL IMPORTANT DIFFERENCES IN EUROQOL-5 DIMENSIONS (EQ-5D) FOR PATIENTS WITH EOSINOPHILIC ESOPHAGITIS: ANALYSIS FROM A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED TRIAL OF BUDESONIDE ORAL SUSPENSION
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(20)30578-7&doi=10.1016/j.jval.2020.04.390
First page :
Section Title :
Open access? : No
Section Order : 10258
Categories :
Tags :
Regions :
ViH Article Tags :